<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BETHANECHOL CHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(be-than'e-kole)<br/><span class="topboxtradename">Duvoid, </span><span class="topboxtradename">Urabeth, </span><span class="topboxtradename">Urecholine<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">direct-acting cholinergic (parasympathomimetic) agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 25 mg, 50 mg tablets; 5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic choline ester with effects similar to those of acetylcholine (ACh). Acts directly on postsynaptic receptors, and
         since it is not hydrolyzed by cholinesterase, its actions are more prolonged than those of ACh.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces muscarinic effects primarily on GI tract and urinary bladder. Increases tone and peristaltic activity of esophagus,
         stomach, and intestine; contracts detrusor muscle of urinary bladder, usually enough to initiate micturition.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute postoperative and postpartum nonobstructive (functional) urinary retention, and for neurogenic atony of urinary bladder
         with retention.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>In selected cases of adynamic ileus, gastric atony and retention, reflux esophagitis, congenital megacolon, familial dysautonomia;
         for prevention and treatment of bladder and salivary gland inhibition induced by tricyclic antidepressants, and for prophylaxis
         and treatment of phenothiazine-induced bladder dysfunction.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>COPD; history of or active bronchial asthma; hyperthyroidism; recent urinary bladder surgery, cystitis, bacteriuria, urinary
         bladder neck or intestinal obstruction, peptic ulcer, recent GI surgery, peritonitis; marked vagotonia, pronounced vasomotor
         instability, AV conduction defects, severe bradycardia, hypotension or hypertension, coronary artery disease, recent MI; epilepsy,
         parkinsonism. Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Urinary retention; bacteriemia.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Retention</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1050 mg b.i.d. to q.i.d. (max: 120 mg/d) <span class="rdroute">SC</span> 2.55 mg t.i.d. or q.i.d. prn<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.2 mg/kg or 0.6 mg/m<sup>2</sup> t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach (1 h before or 2 h after meals) to lessen possibility of nausea and vomiting, unless otherwise advised
            by physician.
         </li>
<li>Determine minimum effective dose: Give 510 mg initially and repeat this dose at 12 h (max: 50 mg), until a satisfactory
            response occurs. Alternatively, give 10 mg followed, at 6 h intervals, by 25 mg, then 50 mg, until desired response obtained.
         </li>
</ul><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Determine minimum effective dose: Give 2.5 mg initially and repeat this dose at 1530 min intervals (max: 4 doses), or
            until a satisfactory response occurs.
         </li>
<li>After inserting needle, aspirate carefully before injecting drug to avoid inadvertent entry into a blood vessel.</li>
<li>
<small>DO NOT</small> give by IM or IV; life-threatening symptoms of cholinergic stimulation can occur.
         </li>
<li>Overdose management: Atropine sulfate 0.61.2 mg for adults administered IM, slow IV, or SC; and 0.01 mg/kg for infants
            and children repeated every 2 h, if necessary.
         </li>
<li>Store at 15°30° C (59°86° F), unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Dose-related. Increased sweating, malaise, headache, substernal pain or pressure, hypothermia. <span class="typehead">CV:</span> Hypotension with dizziness, faintness, flushing, orthostatic hypotension (large doses); mild reflex tachycardia, atrial fibrillation
      (hyperthyroid patients), <span class="speceff-life">transient complete heart block</span>. <span class="typehead">Special Senses:</span> Blurred vision, miosis, lacrimation. <span class="typehead">GI:</span> Nausea, vomiting, abdominal cramps, diarrhea, borborygmi, belching, salivation, fecal incontinence (large doses), urge to
      defecate (or urinate). <span class="typehead">Respiratory:</span> Acute asthmatic attack, dyspnea (large doses). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Bethanechol may cause increases in <span class="alt">serum amylase</span> and <span class="alt">serum lipase,</span> by stimulating pancreatic secretions, and may increase <span class="alt">AST,</span>
<span class="alt">serum bilirubin,</span> and <span class="alt">BSP retention</span> by causing spasms in sphincter of Oddi.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Ambenonium,</b>
<b>neostigmine,</b> other <span class="classification">cholinesterase inhibitors</span> compound cholinergic effects and toxicity; <b>mecamylamine</b> may cause abdominal symptoms and hypotension; <b>procainamide,</b>
<b>quinidine,</b>
<b>atropine,</b>
<b>epinephrine</b> antagonize effects of bethanechol. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed PO. <span class="typehead">Onset:</span> 30 min PO; 515 min SC. <span class="typehead">Peak:</span> 6090 min PO; 1530 min SC. <span class="typehead">Duration:</span> 16 h PO; 2 h SC. <span class="typehead">Distribution:</span> Does not cross bloodbrain barrier. <span class="typehead">Metabolism:</span> Unknown. <span class="typehead">Elimination:</span> Unknown. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and pulse. Observe patient for at least 1 h following SC administration. Report early signs of overdosage: Salivation,
            sweating, flushing, abdominal cramps, nausea.
         </li>
<li>Monitor I&amp;O. Observe and record patient's response to bethanechol, and report any failure of the drug to relieve the particular
            condition for which it was prescribed.
         </li>
<li>Monitor respiratory status. Promptly report dyspnea or any other indication of respiratory distress.</li>
<li>Supervise ambulation as indicated by patient response to drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Make position changes slowly and in stages, particularly from lying down to standing.</li>
<li>Do not stand still for prolonged periods; sit or lie down at first indication of faintness.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>
            							Note: Drug may cause blurred vision; take appropriate precautions.
            						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>